C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
3.950
+0.105 (2.73%)
At close: Dec 20, 2024, 4:00 PM
3.970
+0.020 (0.51%)
After-hours: Dec 20, 2024, 7:31 PM EST
C4 Therapeutics Revenue
C4 Therapeutics had revenue of $15.36M in the quarter ending September 30, 2024, with 38.75% growth. This brings the company's revenue in the last twelve months to $33.67M, up 65.45% year-over-year. In the year 2023, C4 Therapeutics had annual revenue of $20.76M, down -33.25%.
Revenue (ttm)
$33.67M
Revenue Growth
+65.45%
P/S Ratio
7.57
Revenue / Employee
$232,193
Employees
145
Market Cap
278.83M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Accolade | 441.03M |
Procaps Group | 414.10M |
Amylyx Pharmaceuticals | 196.49M |
Zynex | 193.67M |
Vanda Pharmaceuticals | 190.86M |
Sanara MedTech | 78.06M |
Foghorn Therapeutics | 25.52M |
Sera Prognostics | 94.00K |
CCCC News
- 13 days ago - C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader - GlobeNewsWire
- 4 weeks ago - C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewsWire
- 7 weeks ago - C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. - GlobeNewsWire
- 2 months ago - C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit - GlobeNewsWire
- 3 months ago - C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 3 months ago - C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 - GlobeNewsWire
- 3 months ago - C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors - GlobeNewsWire